Can We Use mTOR Inhibitors for COVID-19 Therapy?

Area of Science:

• Immunology
• Virology
• Cellular Biology

Background:

• Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection leads to significant inflammation in the respiratory system.
• The mammalian target of rapamycin (mTOR) is a key signaling protein regulating cell growth, metabolism, proliferation, protein synthesis, and angiogenesis.
• mTOR exists in two complexes, mTORC1 and mTORC2, with distinct roles in mRNA translation, cellular growth, proliferation, and survival.

Purpose of the Study:

• To explore the potential of targeting the mammalian target of rapamycin (mTOR) pathway for therapeutic interventions in SARS-CoV-2 infection.
• To review the role of mTOR in inflammation and viral infections.
• To assess the existing clinical evidence for mTOR inhibitors in treating viral respiratory illnesses.

Main Methods:

• Literature review of studies on SARS-CoV-2, mTOR signaling, and mTOR inhibitors.
• Analysis of the role of mTORC1 and mTORC2 in viral pathogenesis and inflammation.
• Examination of clinical data from trials involving mTOR inhibitors for viral infections like influenza A/H1N1.

Main Results:

• mTOR plays a significant role in the inflammatory response associated with viral infections.
• mTOR inhibitors have demonstrated efficacy in treating severe influenza A/H1N1 pneumonia and acute respiratory failure.
• Approved mTOR inhibitors include sirolimus, everolimus, temsirolimus, and tacrolimus.

Conclusions:

• Modulation of the mTOR pathway presents a potential therapeutic strategy for managing SARS-CoV-2 infection and COVID-19.
• Further research into mTOR inhibitors for COVID-19 treatment is warranted based on their established roles in inflammation and success in other viral infections.